These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

788 related items for PubMed ID: 11320369

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN.
    Circulation; 1999 May 25; 99(20):2658-64. PubMed ID: 10338459
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The clinical profile of the angiotensin II receptor blocker eprosartan.
    Hedner T.
    J Hypertens Suppl; 2002 Jun 25; 20(5):S33-8. PubMed ID: 12184062
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE.
    Arterioscler Thromb Vasc Biol; 2004 Jun 25; 24(6):1043-8. PubMed ID: 15105283
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
    McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J, Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators.
    Circ Heart Fail; 2008 May 25; 1(1):17-24. PubMed ID: 19808266
    [Abstract] [Full Text] [Related]

  • 34. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group.
    Tonkon M, Awan N, Niazi I, Hanley P, Baruch L, Wolf RA, Block AJ.
    Int J Clin Pract; 2000 May 25; 54(1):11-4, 16-8. PubMed ID: 10750252
    [Abstract] [Full Text] [Related]

  • 35. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
    Blanchet M, Sheppard R, Racine N, Ducharme A, Curnier D, Tardif JC, Sirois P, Lamoureux MC, De Champlain J, White M.
    Am Heart J; 2005 May 25; 149(5):938.e1-7. PubMed ID: 15894946
    [Abstract] [Full Text] [Related]

  • 36. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group.
    Diamond JA, Gharavi A, Roychoudhury D, Machac J, Henzlova MJ, Travis A, Phillips RA.
    Curr Med Res Opin; 1999 May 25; 15(1):1-8. PubMed ID: 10216805
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies.
    Rayner B, Jaeger B, Verboom CN, Pascoe M.
    Cardiovasc J S Afr; 2004 May 25; 15(1):32-7. PubMed ID: 14997235
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.